Yanina Jansen

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

Jeroen de Filette, Yanina Jansen, Max Schreuer et al. · The Journal of Clinical Endocrinology & Metabolism · 2016 · 249 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Yanina Jansen, Elisa A. Rozeman, Robert M. Mason et al. · Annals of Oncology · 2019 · 228 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Max Schreuer, Yanina Jansen, Simon Planken et al. · The Lancet Oncology · 2017 · 184 citations

Medicine, Oncology, Pharmacology +16

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen et al. · Journal of Translational Medicine · 2016 · 138 citations · Full text

Medicine, Molecular Biology, Oncology +17

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Teofila Seremet, Yanina Jansen, Simon Planken et al. · Journal of Translational Medicine · 2019 · 117 citations · Full text

Medicine, Clinical Sciences, Oncology +17